humanitarian Archived signal Translated · Español · 2–5m lag

Medicamentos para el hombre Informe Público Europeo de Evaluación (EPAR): Pebrilzo, pertuzumab, Estado: Opinión

Medicamentos para el hombre Informe público europeo de evaluación (EPAR): Zumrad, sasaclimab, Estado: retirada de la solicitud

Reported by EMA What Is New Sep 18, 2026 · 10:05 UTC

Read the complete report at EMA What Is New ↗

Verification notice

IntelMap indexes open-source reporting. This page identifies what a source reported; it does not independently confirm the claim.

INCIDENT FUSION

12 reports · 2 sources

EMA What Is NewMedicamentos para el hombre Informe Público Europeo de Evaluación (EPAR): Pebrilzo, pertuzumab, Estado: Opinión10:05 UTC EMA What Is NewHuman medicines European public assessment report (EPAR): Frehemgo, denecimig, Status: Opinion10:05 UTC EMA What Is NewMedicamentos para el hombre Informe Público Europeo de Evaluación (EPAR): Sepalna, senaparib, Estado: Opinión10:05 UTC EMA What Is NewHuman medicines European public assessment report (EPAR): Inijaq, tofacitinib, Status: Opinion10:05 UTC EMA What Is NewHuman medicines European public assessment report (EPAR): Ruxolitinib Zentiva, ruxolitinib, Status: Opinion10:05 UTC EMA What Is NewHuman medicines European public assessment report (EPAR): Lifyorli, relacorilant, Status: Opinion10:05 UTC EMA What Is NewHuman medicines European public assessment report (EPAR): Adcomfo, omalizumab, Status: Opinion10:05 UTC EMA What Is NewHuman medicines European public assessment report (EPAR): Zeydovio, glepaglutide, Status: Opinion10:05 UTC EMA What Is NewHuman medicines European public assessment report (EPAR): Povofortay, povorcitinib, Status: Opinion10:05 UTC EMA What Is NewMedicamentos para el hombre Informe Público Europeo de Evaluación (EPAR): Sepalna, senaparib, Estado: Opinión10:05 UTC EMA What Is NewHuman medicines European public assessment report (EPAR): Ruxolitinib Zentiva, ruxolitinib, Status: Opinion10:05 UTC EMA What Is NewHuman medicines European public assessment report (EPAR): Povofortay, povorcitinib, Status: Opinion10:05 UTC

INCIDENT EVOLUTION

2 recorded states

Sep 18 · 14:50 UTC

Signal first indexedP2 · 99% quality · 2 sources

Sep 18 · 14:51 UTC

Headline updatedP2 · 99% quality · 2 sources

Explore this day in the archive →